Molecular Docking Studies of Bioactive Constituents of Long Pepper, Ginger, Clove and Black Pepper to Target the Human Cathepsin-L Protease: As a Natural Therapeutic Strategy against SARS-Cov-2
Keywords:molecular docking, SARS-Cov-2, human cathepsin-L protease, natural bioactive components
Human cathepsin-L protease is involved in the cleavage of S protein of SARS-Cov2 virus and activates the membrane fusion which mediates the entry of the virus into the host cell. Thus, it suggests the cathepsin-L protease is critical for the entry of SARS-Cov2. Currently, chemically synthesized cathepsin-L inhibitors are present, but, the consumption of chemically synthesized drugs is also an alarming stage due to its side effects, illness and age reduction. In this study, natural bioactive constituents of Long pepper, Ginger, clove and black pepper that has been widely known for antiviral effect and other medicinal properties were used for molecular docking against the human cathepsin-L receptor (PDB ID 2XU1). Molecular docking (using a software, Autodock 4.2) were performed on Bioactive constituents of Long pepper, Ginger, Clove and Black pepper against the human cathepsin-L protease and elucidate the binding energies, visualization and analysis of interacting residue (using Discovery studio) at the docking site of cathepsin-L protease and compared the docking analysis of these bioactive constituents with pre-clinical cathepsin-L inhibitor (Pub Chem CID: 16725315). The pharmacokinetic properties and toxicity evaluation were calculated by Datawarrior and Osiris Molecular Property explorer software respectively. Many bioactive constituents from Long pepper, Ginger, Clove and Black pepper have shown significant binding affinity, docking interactions and acceptable pharmacokinetic properties with the human Cathepsin L Protease. PiperolactamA constituent of Long pepper and Kaempferol constituent of clove were found to be more acceptable natural therapeutic compounds among other selected bioactive constituents with the highest binding affinity (Kcal/mol) -9.4 and -9.3 respectively.
Received: 21 August 2023 | Revised: 22 December 2023 | Accepted: 25 December 2023
Conflicts of Interest
The authors declare that they have no conflicts of interest to this work.
How to Cite
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.